New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

Recursion reported positive new Phase 2 analyses from the ongoing TUPELO trial of REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis. Most patients had reductions in larger, higher-risk polyps and lower-GI polyp burden; the release provided no numerical effect sizes. The findings build on upper-GI results announced October 15, 2026, and were presented at the CGA-IGC Annual Meeting.

Analysis

The investable question is whether the polyp reductions translate into durable clinical benefit and a tolerable risk profile for chronic use—not whether the result validates AI drug discovery broadly. In FAP, changes in polyp burden are clinically relevant, but this update alone does not establish reduced cancer risk, delayed surgery, or a favorable benefit-risk balance. The oral, whole-GI-tract potential could matter if confirmed; conversely, systemic MEK1/2 inhibition may face a demanding safety bar in a population needing long-term management. The article supplies no effect sizes, duration, adverse-event detail, comparator, or regulatory path, so commercial value and probability of approval cannot be responsibly quantified.

Near term, positive clinical sentiment may support RXRX, but a presentation and company-reported analyses are not equivalent to a full, independently scrutinized dataset. Over 1–3 months, watch for detailed efficacy and safety disclosures, trial-design updates, and evidence that benefits persist. Over 6–18 months, the key value inflection is whether clinical benefit and tolerability support a credible path to registration and adoption. A reversal would be weak durability, clinically meaningful toxicity, or no evidence the biomarker-like polyp changes affect patient outcomes. The contrarian risk is extrapolating one asset’s signal into platform-wide validation; the opposite risk is dismissing a potentially useful rare-disease therapy before full data are available.

Key Decisions for Investors

• Do not underwrite a broad AI-biotech re-rating from this update. Treat it as an asset-specific clinical signal; no platform-wide revenue or valuation conclusion follows.
• For existing RXRX exposure, avoid adding solely on the headline. Consider trimming into an outsized event-driven rally if the move prices in approval-like certainty; retain exposure only in line with tolerance for clinical-trial downside.
• Watch for the missing decision-grade data: magnitude and durability of polyp reduction, patient-level consistency, adverse events and discontinuations, comparator/context, and whether outcomes support fewer procedures or improved patient outcomes.
• Reassess on the next detailed dataset or trial/regulatory update. The thesis weakens materially if benefit is not sustained or safety limits chronic dosing; it strengthens if efficacy is durable, tolerability is acceptable, and a credible registration path is clarified.